4月18日，据CDE官网消息，盛禾（中国）生物制药有限公司联合申请药品“IAH0968”，获得临床试验默示许可，受理号CXSL2500141。
公示信息显示，药品“IAH0968”适应症：经奥沙利铂、氟尿嘧啶类和伊立替康治疗失败的 RAS/RAF 野生型 HER2 阳性晚期结直肠癌。
盛禾（中国）生物制药有限公司，成立于2018年，位于南京市，是一家以从事医药制造业为主的企业。企业注册资本18768.2553万人民币，实缴资本10148.94万人民币。
通过天眼查大数据分析，盛禾（中国）生物制药有限公司共对外投资了1家企业，参与招投标项目14次，知识产权方面有商标信息33条，专利信息69条，此外企业还拥有行政许可57个。
主要股东信息显示，盛禾（中国）生物制药有限公司由盛禾医药科技（浙江安吉）有限公司持股100%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.